OXT and behavioral variant of frontotemporal dementia: Finger et al. [26] conducted a randomized, parallel-group, double-blind, placebo-controlled study using a dose-escalation design to test the safety and tolerability of three clinically feasible doses of intranasal oxytocin (24, 48, or 72 IU) administered twice a day for one week in 23 patients with bvFTD or semantic dementia with concomitant behavioral disorders.